PRX-07034
 | |
| IUPAC ime | |
|---|---|
N-[1-(5-hloro-2,3-dimetoksifenil)etil]-2-metilsulfonil-5-piperazin-1-ilanilin | |
| Klinički podaci | |
| Način primene | Oralno |
| Pravni status | |
| Pravni status |
|
| Identifikatori | |
| ATC kod | none |
| PubChem | CID 11532574 |
| Hemijski podaci | |
| Formula | C21H29Cl2N3O4S |
| Molarna masa | 490,44 g/mol |
| |
PRX-07034 je selektivni antagonist 5-HT6 receptora.[1] On utiče na kogniciju, poboljšava memoriju, i potencijalno umanjuje unos hrane i telesnu težinu kod glodara.[1][2][3][4]
Reference
[уреди | уреди извор]- ^ а б „Science Links Japan | PRX-07034, a Potent and Selective 5-HT6 Receptor Antagonist, Reduces Food Intake and Body Weight in Rats”. Архивирано из оригинала 29. 02. 2012. г.
- ^ Fone KC (2008). „An update on the role of the 5-hydroxytryptamine6 receptor in cognitive function”. Neuropharmacology. 55 (6): 1015—22. PMID 18655798. doi:10.1016/j.neuropharm.2008.06.061.
- ^ „Science Links Japan | Combination of sub-threshold doses of Aricept and PRX-07034, a novel 5-HT6 receptor antagonist, enhances Novel Object Discrimination (NOD) memory”. Архивирано из оригинала 29. 02. 2012. г.
- ^ Halford JC, Harrold JA, Boyland EJ, Lawton CL, Blundell JE (2007). „Serotonergic drugs : effects on appetite expression and use for the treatment of obesity”. Drugs. 67 (1): 27—55. PMID 17209663. Архивирано из оригинала 05. 01. 2013. г. Приступљено 12. 12. 2012.
Spoljašnje veze
[уреди | уреди извор]
- Preclinical Data on Predix Pharmaceuticals' 5-HT6 Antagonist for Obesity and Cognitive...
- Epix’s Experimental Drug PRX-07034 Shows Potential Benefit on Cognition, Obesity